BTK
Les inhibiteurs de la tyrosine kinase de Bruton (BTK) sont des composés qui ciblent spécifiquement et inhibent la BTK, une enzyme cruciale impliquée dans la signalisation du récepteur des cellules B et la régulation de l'angiogenèse. La BTK joue un rôle significatif dans la prolifération et la survie des cellules cancéreuses, en particulier dans les malignités hématologiques. En inhibant la BTK, ces composés peuvent perturber l'angiogenèse et la croissance tumorale, ce qui les rend précieux en thérapie anticancéreuse. Chez CymitQuimica, nous offrons une gamme d'inhibiteurs de la BTK de haute qualité pour soutenir vos recherches en oncologie, immunologie et angiogenèse.
169 produits trouvés pour "BTK".
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
SJF620 hydrochloride
CAS :SJF620 hydrochloride is a PROTAC that utilizes a lenalidomide analog to recruit CRBN and ligands to target Btk, exhibiting a DC50 of 7.9 nM [1].Formule :C41H45ClN8O7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :797.3Ibrutinib dimer
CAS :Ibrutinib dimer is an impurity of Ibrutinib. IIbrutinib dimer is a Dimer of Ibrutinib. Ibrutinib is an irreversible Btk inhibitor (IC50: 0.5 nM).Formule :C50H48N12O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :880.99PCI-33380
CAS :PCI-33380 is an irreversible inhibitor of Bruton's Tyrosine Kinase.Formule :C46H52BF2N11O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :855.8Tyrosinase-IN-16
CAS :Tyrosinase-IN-16 inhibited tyrosinase.Formule :C8H6BrN3SDegré de pureté :99.94%Couleur et forme :White SolidMasse moléculaire :256.12PROTAC BTK Degrader-12
CAS :PROTAC BTK Degrader-12 (EXAMPLE 19) is a PROTAC-based BTK degrader, featuring a structure where the BTK ligand and linker are highlighted in pink and black, the linker in black, and the VHL ligand in blue.Formule :C47H54N12O4Couleur et forme :SolidMasse moléculaire :851.01PROTAC BTK Degrader-10
CAS :PROTAC BTK Degrader-10 (Example 1P) is a PROTAC compound that targets BTK for degradation. It is applicable in the research of chronic lymphocytic leukemia (CLL). [Pink: ligand for target protein; Black: linker; Blue: ligand for E3 ligase Cereblon].Formule :C42H49N11O4Couleur et forme :SolidMasse moléculaire :771.91PROTAC BTK Degrader-9
PROTACBTK Degrader-9 (compound 23) is a potent PROTACs degrader that specifically targets BTK. It effectively downregulates the RANKL-activated BTK-PLCγ2-Ca2+-NFATc1 signaling pathway. Consequently, PROTACBTK Degrader-9 inhibits osteoclastogenesis and reduces alveolar bone resorption in a mouse model of periodontitis.Formule :C46H52FN13O5Couleur et forme :SolidMasse moléculaire :885.41984L18I
L18I is a PROTAC (Proteolysis Targeting Chimera) that targets Btk to mitigate inflammation in autoimmune diseases. The components of L18I include the PROTAC target protein ligand IBT6A, the PROTAC linker Propargyl-PEG3-alcohol, and the E3 ubiquitin ligase ligand Lenalidomide-Br. Notably, the active control for the target protein ligand is IBT6A-CO-ethyne, while the conjugate of the E3 ubiquitin ligase ligand with the linker is Lenalidomide-C3-PEG3-N3.Formule :C47H51N11O8Couleur et forme :SolidMasse moléculaire :897.98Ibrutinib-biotin
CAS :Ibrutinib-biotin probe links Ibrutinib to biotin, with IC50 0.755-1.02 nM for BTK (patent WO2014059368A1).Formule :C56H80N12O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1097.39GBD-9
CAS :GBD-9, a dual-mechanism degrader, effectively promotes the degradation of BTK and GSPT1 through recruitment of E3 ligase cereblon (CRBN).Formule :C44H47N9O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :797.9BTK inhibitor 19
CAS :BTK inhibitor 19 is a highly selective, covalent BTK inhibitor ( IC 50 = 2.7 nM).Formule :C25H24F3N7O3Couleur et forme :SolidMasse moléculaire :527.508FDA-Approved Kinase Inhibitor Library
A unique collection of xnum kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.Couleur et forme :LiquidRef: TM-L1610
1mgÀ demander10μL*10mM (DMSO)À demander20μL*10mM (DMSO)À demander30μL*10mM (DMSO)À demander50μL*10mM (DMSO)À demander100μL*10mM (DMSO)À demander250μL*10mM (DMSO)À demanderPROTAC BTK Degrader-8
PROTACBTK Degrader-8 (compound 3) is an efficient PROTAC BTK degrader with a linker that can couple with ADC antibodies to form PAC.Formule :C80H94F2N14O20P2Couleur et forme :SolidMasse moléculaire :1670.62121LFM-A13
CAS :LFM-A13 is a highly selective BTK inhibitor; IC50 2.5 uM; targets catalytic domain; severs BCR signaling; anti-leukemic; autoimmune disease and lymphocytic leukemia research.Formule :C11H8Br2N2O2Degré de pureté :99.50%Couleur et forme :White SolidMasse moléculaire :360BTK-IN-5
CAS :BTK-IN-5 is a covalent inhibitor of Bruton's tyrosine kinase (BTK) designed for the treatment of medical conditions including cardiovascular diseases,Formule :C23H32N4O5Couleur et forme :SolidMasse moléculaire :444.532PROTAC BTK Degrader-1
CAS :Potent, selective oral PROTAC BTK Degrader-1; IC50: 34.51 nM (WT), 64.56 nM (BTK-481S); reduces BTK protein, inhibits tumors.Formule :C43H43N9O4Couleur et forme :SolidMasse moléculaire :749.86CNX-500
CAS :CNX-500: covalent Btk inhibitor linked to biotin, IC50 0.5 nM, low effect on EGFR and Src kinases.Formule :C48H68N10O9SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :961.18PROTAC BTK Degrader-2
CAS :PROTAC BTK Degrader-2, a potent degrader of BTK through the PROTAC mechanism, effectively diminishes BTK protein levels [1].Formule :C47H54F2N8O13Couleur et forme :SolidMasse moléculaire :976.97BRK inhibitor P21d hydrochloride
CAS :BRK inhibitor P21d HCl targets breast tumor kinase with 30 nM IC50, suppresses p-SAM68 at 52 nM, useful for in vivo breast cancer research.Formule :C23H23ClFN7O2Couleur et forme :SolidMasse moléculaire :483.93PROTAC BTK Degrader-11
CAS :PROTAC BTK Degrader-11 is a PROTAC degrader that targets and degrades BTK with a DC50 of 1.7 nM. It is utilized in oncological research.Formule :C48H55N11O4Couleur et forme :SolidMasse moléculaire :850.02
